| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 890 | 2014 |
| A phase 3 randomized trial of voxelotor in sickle cell disease E Vichinsky, CC Hoppe, KI Ataga, RE Ware, V Nduba, A El-Beshlawy, ... New England Journal of Medicine 381 (6), 509-519, 2019 | 554 | 2019 |
| Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment PG Richardson, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... Blood, The Journal of the American Society of Hematology 127 (6), 713-721, 2016 | 192* | 2016 |
| Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The Lancet Haematology 3 (11), e506-e515, 2016 | 164 | 2016 |
| Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity AH ElGhandour, M El Sorady, S Azab, M ElRahman Hematology Reviews 1 (1), 2009 | 39 | 2009 |
| Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1 JF San-Miguel, VT de Moraes Hungria, SS Yoon, W Wiktor-Jedrzejczak, ... Blood 118 (21), 3976, 2011 | 24 | 2011 |
| Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial JF San‐Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... British Journal of Haematology 179 (1), 66-74, 2017 | 16 | 2017 |
| Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). JF San-Miguel, P Moreau, SS Yoon, MA Dimopoulos, VTM Hungria, ... Journal of Clinical Oncology 30 (15_suppl), e18572-e18572, 2012 | 13 | 2012 |
| Final analysis of overall survival from the phase 3 Panorama 1 trial of panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... Blood 126 (23), 3026, 2015 | 12 | 2015 |
| Bone marrow angiogenesis in patients with hematological malignancies: role of VEGF M El-Sorady, MA Elrahman, M El-Bordini, A El-Ghandour, A El-Said, ... Journal of the Egyptian National Cancer Institute 12, 131-136, 2000 | 12 | 2000 |
| Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined … JF San Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... Journal of Clinical Oncology 33 (15_suppl), 8526-8526, 2015 | 11 | 2015 |
| Characterization of the incidence and management of gastrointestinal toxicity in the phase 3 Panorama 1 study of panobinostat plus bortezomib and dexamethasone versus placebo … PG Richardson, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... Blood 124 (21), 2120, 2014 | 7 | 2014 |
| Level of Pentraxin-3 in Patients with Acute Leukemia in Septicemia and Its Prognostic Value HM Ashraf Elghandour, Hashem Naenaa, Mohamed Eldefrawy, Magdy Elbordeny International Blood Research & Reviews 4 (1), 1-7, 2015 | 6 | 2015 |
| Efficacy and safety based on duration of treatment of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma in … J San Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... Blood 124 (21), 4742, 2014 | 6 | 2014 |
| Subgroup analysis by prior treatment among patients with relapsed or relapsed and refractory multiple myeloma in the panorama 1 study of panobinostat or placebo plus bortezomib … H Einsele, P Richardson, V Hungria, SS Yoon, M Beksac, M Dimopoulos, ... FERRATA STORTI FOUNDATION, 2015 | 4 | 2015 |
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … SS Yoon, M Beksac, MA Dimopoulos, A Elghandour, WW Jedrzejczak, ... LANCET ONCOLOGY 15 (11), 1195-1206, 2014 | 4 | 2014 |
| Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE RSM Wong, İ Yavaşoğlu, MA Yassin, P Tarkun, SS Yoon, X Wei, ... Blood Advances 7 (17), 4773-4781, 2023 | 3 | 2023 |
| FXYD domain containing ion transport regulator 3 (FXYD3) is over-expressed in germinal centre derived aggressive lymphomas and plasma cell myeloma C Peron, A Visani, A Weber, F Rigotti, Y Ahmed, S Khattab, ... Biomed. J. Sci. Techn. Res 15, 11042-11051, 2019 | 2 | 2019 |
| NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in acute leukemia MM El Bordiny, A El Ghandour, AR Mansour, AS El Hadidi, RAM Farag The Egyptian Journal of Haematology 41 (2), 81-86, 2016 | 2 | 2016 |
| Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and … PGRVTMHSSYMBMADAEWWJAGTNNNSRLSJHPMSLJHLHEMSBRBCCJF San-Miguel Clinical Lymphoma Myeloma and Leukemia, 2015 | 2 | 2015 |
Jay Hyung LeeUniversity of Southern CaliforniaVerified email at usc.edu
